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After cardiac injury, the mammalian adult heart has a very limited capacity to regenerate,
due to the inability of fully differentiated cardiomyocytes (CMs) to efficiently proliferate.
This has been directly linked to the extracellular matrix (ECM) surrounding and connecting
cardiomyocytes, as its increasing rigidity during heart maturation has a crucial impact
over the proliferative capacity of CMs. Very recent studies using mouse models have
demonstrated how the ECM protein agrin might promote heart regeneration through
CMs de-differentiation and proliferation. In maturing CMs, this proteoglycan would act
as an inducer of a specific molecular pathway involving ECM receptor(s) within the
transmembrane dystrophin-glycoprotein complex (DGC) as well as intracellular Yap,
an effector of the Hippo pathway involved in the replication/regeneration program of
CMs. According to the mechanism proposed, during mice heart development agrin gets
progressively downregulated and ultimately replaced by other ECM proteins eventually
leading to loss of proliferation/ regenerative capacity in mature CMs. Although the role
played by the agrin-DGC-YAP axis during human heart development remains still largely
to be defined, this scenario opens up fascinating and promising therapeutic avenues.
Herein, we discuss the currently available relevant information on this system, with a
view to explore how the fundamental understanding of the regenerative potential of this
cellular program can be translated into therapeutic treatment of injured human hearts.
Keywords: heart regeneration, agrin, dystrophin-glycoprotein complex, dystroglycan, laminin, YAP, Hippo
pathway, cardiomyocyte proliferation
INTRODUCTION
The repair of damaged hearts represents one of the most critical challenges in cardiovascular
medicine, since mammalian cardiomyocytes (CMs) lose their proliferative potential very
early in life, after which point hypertrophic processes become responsible for most of
the remaining heart growth. Therefore, upon injury, CMs are replaced by fibrotic tissue,
often with deleterious consequences. Recent advances in understanding the endogenous
program(s) regulating the proliferation of cardiomyocytes at the molecular level [reviewed
in Deshmukh et al. (2019), Heallen et al. (2019), Ali et al. (2020)] hold great promise for
the development of new approaches to heart regeneration based on cell cycle re-activation.
Unfortunately, a full characterization of the developmental pathway(s) of the mammalian heart
and specifically of CMs, is hindered by an intrinsic difficulty in understanding the exact timing
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and interchange of proliferation and differentiation events
(Velayutham et al., 2019). Unlike certain fish and amphibian
species (Zhang et al., 2013), mammalian CMs can follow a
regenerative program only during a limited postnatal period.
Due to important differences in the developmental milestones
of specific mammalian species, the exact time frame of
fetal/postnatal proliferative heart growth has however only been
determined in fewmodel systems. The best characterized of these
is the mouse model, in which full proliferation of CMs lasts
for only the first few days postnatally, possibly until postnatal
day 2 (P2), with the regenerative program already shut down
at P7, when CMs have stopped proliferating and switched to
a hypertrophic program (Porrello et al., 2011; Notari et al.,
2018). Some recent crucial findings in mice challenge in part
the idea that this differentiation program cannot be somehow
modulated, and proliferation re-activated (Bassat et al., 2017;
Morikawa et al., 2017). Following previous work proving how
the rigidity of the extracellular matrix (ECM) strongly influences
heart development (Yahalom-Ronen et al., 2015), and specifically
CMsmaturation, Bassat et al. used a series of elegant experiments
to identify the proteoglycan agrin as an ECM component that
promotes cardiomyocyte proliferation. Interestingly, they found
that this protein is involved in neonatal heart repair and is
only enriched in the matrix in the very first postnatal days,
while downregulated by the P7 stage. Crucially, administration
of recombinant agrin to juvenile and adult infarct mouse models
was sufficient to boost cardiac regeneration through reactivation
of the CMs proliferative program.
Existing studies investigating the role of agrin in other
biological organs and systems are invaluable for beginning
to piece together the mechanisms of action of agrin in the
heart. In recent years, agrin has been revealed to play an
important role in cancer development. An increase in agrin
has been demonstrated in cancerous cells, and studies using
experimental models have shown that addition of agrin promotes
cancer whilst agrin depletion slows tumor growth (Chakraborty
et al., 2015, 2017; Lv et al., 2017; Rivera et al., 2018). It
is now known that agrin forms a mechanotransductive link
between the ECM and the transcriptional co-activators YAP
(Yes associated protein) and TAZ (transcriptional activator
with PDZ binding motif) [reviewed in Chakraborty and Hong
(2018), Xiong and Mei (2017)]. YAP and TAZ activate the
transcription of many pro-proliferative and anti-apoptopic genes
and are themselves controlled by many upstream factors,
including the Hippo signaling pathway which regulates growth
via YAP phosphorylation, thus sequestering it in the cytosol and
preventing its transcriptional activity (Figure 1A). Experiments
using liver tumor cells suggest that the increase in ECM stiffness
which is observed in at least some cancerous tissues results
in increased levels of extracellular agrin (Chakraborty et al.,
2017). Agrin binds to the cell via Lrp4 (low density lipoprotein
receptor related protein 4), which in turn activatesMuSK (muscle
specific kinase 4). This results in activation of the FAK-ILK-
PAK1 (Focal Adhesion Kinase—Integrin Linked Kinase—p21
Activated Kinase) signaling axis, resulting in inhibition of Hippo
signaling and consequent nuclear localization of YAP/TAZ. YAP
transcriptional activity itself is known to increase the ECM
stiffness possibly due to enhanced agrin expression, and it
has been suggested that a positive feedback loop thus exists
between agrin levels (through ECM stiffness increase) and YAP
transcriptional activity, in a functional mechanotransduction
network that promotes uncontrolled proliferation (Calvo et al.,
2013; Chakraborty and Hong, 2018) (Figure 1A). Similar
signaling pathways exists in neuromuscular junctions, where
agrin is responsible for recruiting acetylcholine receptors. Agrin
secreted from nerve terminals activates YAP via Lrp4/MuSK
signaling; this results in the aggregation of acetylcholine
receptors on the postsynaptic muscle cells (Zhao et al., 2017;
Chakraborty and Hong, 2018). Agrin has also been demonstrated
to interact with dystroglycan (DG) at the neuromuscular
junction; DG is a pivotal member of the large transmembrane
complex connecting the ECM with the cytoskeleton [namely
the dystrophin-glycoprotein complex (DGC)], which is necessary
for stabilization of acetylcholine receptor clusters (Ervasti and
Campbell, 1993; Jacobson et al., 2001). In line with these
precedents, a role for agrin in similar pathways have been
demonstrated to exist in the heart. Bassat et al. determined
that agrin promotes heart regeneration by interacting with the
DGC on the CMs cell surface, thus preventing its assembly into
the stable adult form. Specifically, the interaction of agrin with
the extracellular α-DG on CMs would influence the binding
properties of the transmembrane/cytoplasmic β-subunit of DG,
favoring its binding to dystrophin over that to YAP. Similarly to
what described for cancer growth, YAP is known to be involved
in heart growth through CM proliferation which, unlike in other
tissues, is inhibited postnatally due to the activity of upstream
kinases of the Hippo pathway (Von Gise et al., 2012; Xin et al.,
2013). The view proposed by Bassat et al. was corroborated
and complemented by equally important findings from the
James Martin’s laboratory which showed how, during heart
maturation, YAP gets phosphorylated by the Hippo pathway and
consequently establishes a stable interaction with the cytodomain
of β-DG in the adult tissues (Morikawa et al., 2017). Such
interaction would sequester YAP at the cell periphery, thus
preventing it from exerting its proliferation-inducing activity in
the nucleus. All this evidence has been put together to envisage
a possible molecular mechanism linking the axis agrin-DGC-
YAP to heart tissue proliferation, in which during development
and very early after birth the interaction of agrin with α-DG
would interfere with the proper assembly of β-DG into the
DGC, ultimately preventing the tethering of YAP. During cardiac
maturation, this arrangement would change since on one hand
YAP would get actively phosphorylated by the Hippo signaling
pathway, on the other agrin would be replaced by a different,
yet unidentified, ECM component (see below), thus allowing
for proper DGC assembly. These two events would lead to the
locking of phospho YAP at the inner side of the cell surface
through β-DG binding (Figure 1B). A series of evidences shows
how, in this proposed mechanism, laminin represents a strong
candidate to take over from agrin in the binding to the DGC axis
during cardiac muscle development, at least at the later stages. It
was in fact shown that embryonic stem cells carrying mutations
in laminin 211, although differentiating normally in vitro into
contracting myotubes, eventually undergo detachment and death
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FIGURE 1 | (A) Role of agrin and YAP in carcinogenesis. In healthy tissue, the Hippo signaling pathway regulates transcription via phosphorylation of YAP, which results
in its confinement out of the cell nucleus. In cancerous tissue an increase in ECM stiffness is associated with increased levels of extracellular agrin. Agrin binds to the
receptor Lrp4, which activates MuSK, eventually promoting a signaling cascade involving the FAK-ILK-PAK1 axis. This results in the inhibition of the Hippo pathway
that in turn leads to an increase in unphosphorylated YAP. The activity of YAP in the nucleus promotes not only cell-cycle and division but also a further increase in
ECM stiffness, possibly following enhanced agrin expression, in a positive feedback mechanism that leads to uncontrolled proliferation. (B) Schematic of the role of
agrin in mouse cardiomyocyte (CM) proliferation as proposed in Bassat et al. (2017). In neonates, binding of agrin to the α-subunit of dystroglycan (DG) interferes with
its correct assembly within the dystrophin-glycoprotein complex (DGC), and ultimately prevents the β-subunit from binding the transcription factor YAP, whose activity
in the nucleus promotes CM proliferation. With maturation, replacement of agrin with a different protein (probably laminin) of the extracellular matrix (ECM) allows for a
stable assembly of the DGC, so that β-DG can bind and sequester phosphorylated YAP out of the nucleus, thus eventually hindering CM proliferation. The timing and
mechanism of YAP phosphorylation, as well as of α-DG glycosylation, have to be determined yet, and might have a role in the molecular pathway. The dashed arrow
between the two panels indicates the potential re-activation of CM proliferation induced by controlled delivery of exogenous agrin to injured cardiac tissue.
(Kuang et al., 1998). Together with the evidence that mutations
or complete lack of laminin 211 are known to cause severe
forms of congenital muscular dystrophy (CMD), these results
stress the important role of laminin for adult skeletal muscle
stabilization (Yurchenco et al., 2018) and cardiac muscle stability
(Nguyen et al., 2019). Other laminins too (including laminin
511, 521, and 221) are known to play an important role for the
differentiation of stem cells into cardiomyocytes (Wang et al.,
2019; Yap et al., 2019; Chanthra et al., 2020). Recent evidence
from studies in Drosophila suggests the possible involvement of
β-DG in the Hippo signaling pathway as a mechano-receptor
within muscle cells (Yatsenko et al., 2020), thus it is worth noting
that the DG-Hippo pathway axis might have an evolutionarily
conserved role in mediating muscle growth and regeneration.
Although it is well-known that the composition of cardiac ECM,
and thus its mechanosensing properties, play a fundamental
role in heart development (Parker and Ingber, 2007; Garoffolo
and Pesce, 2019), whether agrin regulates cardiac ECM stiffness,
similarly to its role in hepatic cancer cells, is unknown. It will
be certainly worth to investigate this point further, in order to
understand whether, irrespective of the ECM receptors involved,
agrin employs a similar strategy to stimulate proliferation of CMs
and cancer cells.
A NEW HOPE FOR CARDIAC
REGENERATION IN MAMMALS?
Aside from the fact that several aspects of the proposed
mechanism remain unclear (see some of the points below), the
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BOX 1 | Open questions on the cardiac regenerative role of the agrin-DG-
Yap axis.
Open questions:
• How is the balance between agrin and laminin in binding to their receptor
α-DG controlled/modulated?
• What is the impact of this agrin-dependent mechanism on CM
proliferation during mouse heart growth?
• Does a similar pathway exist in human cardiac development?
• If so:
1. What is the exact timeframe of the switch in humans?
2. What is the contribution of the agrin-driven pathway to CM
proliferation and to the overall development of human heart?
3. Can we harness this pathway therapeutically to treat cardiac injury in
humans without deleterious effects?
fundamental question arising is whether a similar mechanism
is employed also by human heart. A pretty tricky question
indeed, in the face of the complex and still elusive task of
establishing a correlation between the developmental stages of
different mammals that has to be added to the intrinsic challenge
posed by development studies of the human heart. With a focus
on the molecular aspects and on the therapeutic translational
potential of agrin in human medicine, we have tried to highlight
and discuss some of the open points (summarized in Box 1).
Role of ECM in Cardiac Regeneration:
Agrin vs. Laminin, how Would Molecular
Specificity Be Controlled?
The data collected by Bassat et al. (2017) using mouse models led
them to propose that the regenerative program of CMs is directly
linked to the levels of agrin in the ECM, which decrease over
time to aminimum reached by P7 (likely earlier), when CMs have
already switched to the hypertrophic program. Following this line
of enquiry, the time window was revealed to be even shorter.
Recent mouse experiments employing heart apical amputation
as a tool to analyze possible regenerative pathways (Notari et al.,
2018) established in fact that the timing at which CMs full
proliferative program(s) can be triggered is even tighter than the
postnatal period P1-P7 previously reported (Porrello et al., 2011,
2013). Indeed, a high degree of regeneration was observed only
at P1, with the speed lowering considerably at P2–P3. This would
suggest that the window available for fully inducing massive CM
proliferation could be as short as 24 h after birth. Based on an
overall transcriptomic analysis, the same study proposes that
extracellular matrix proteins, rather than intracellularly acting
cardiac fibers or transcription factors, are the most likely to
influence this process by affecting/regulating the mechanical
degree of stiffness. This would point to a predominantly “outside-
inside” nature of the overall proliferation program, similarly to
what has been shown in cancer cells, although the molecular
mechanisms underlying it are yet to be elucidated.
The work of Bassat et al. clearly shows that the levels of agrin
in mice are halved at P7, although how the protein changes
between P1 and P7 is still unknown. As a matter of fact, the exact
timing at which agrin ceases to have a measurable effect on the
regeneration program remains to be debated. The only available
data on the very first days after birth are those of Notari et al.,
and show how the expression levels of agrin (and its receptor
dystroglycan) do not change between P1 and P2 [see Notari et al.
(2018), Figure S5C]. With regard to the role of the agrin axis,
there are two possible explanations for the lack of regenerative
potential already observed at P2: (i) if it is laminin that replaces
agrin during heart maturation, it could become over-expressed
by P2 and therefore make a take-over on agrin because they
display a similar affinity toward α-DG [see Sciandra et al. (2013)],
(ii) post-P2, additional factors could intervene that favor the
binding of laminin to α-DG over agrin. Notably, western blots
reveal the presence of laminin already at P1 but a slight raise
(∼1.3 times) of its levels at P2 (Notari et al., 2018), so not
only could either hypothesis be correct, but the two mechanisms
could coexist.
From the DGC receptor point of view, a specific molecular
aspect that plays an important role in the binding to α-DG
is the degree of glycosylation of α-DG itself. For example,
in some dystroglycanopathies a significant reduction of α-DG
glycosylation (hypoglycosylation) leads to a drop in laminin
binding affinity, inducing severe muscular dystrophy phenotypes
such asWalker-Warburg Syndrome or Muscle-Eye-Brain disease
(Falsaperla et al., 2016; Brancaccio, 2019). It is known that
cardiac α-DG is slightly less glycosylated than the skeletal
muscle one (Brancaccio et al., 1995) and more glycosylated
than brain α-DG (McDearmon et al., 2006). However, in
chickens the affinity of cardiac α-DG to laminin-111 is still
very high (Brancaccio et al., 1995), and agrin has only a
slightly reduced affinity for brain DG relative to skeletal muscle,
kidney, or lung (Gesemann et al., 1998). Overall, these data
suggest that the effect of differential tissue glycosylation of
α-DG on its interaction with both laminin and agrin might
be small. Nonetheless, considering that the glycosylation shell
of brain α-DG is similar to that of early embryonic α-DG
(Leschziner et al., 2001), it may well be that agrin and laminin
could display some minor although physiologically relevant
differences in affinity toward α-DG tissue isoforms based on
their differential degree of glycosylation at various stages of
development. To the best of our knowledge no data on this
are available in the literature, but if that was the case, it would
be important to investigate with some direct protein analysis
whether and when there is a transition from cardiac embryonic
(less-glycosylated) to cardiac adult (more-glycosylated) α-DG
in cardiac myocytes and fibers. From a translational point
of view, such knowledge could guide the optimization of
exogenous recombinant agrin that preferentially interacts with
fully glycosylated α-DG over laminin in differentiated CMs, as
to increase its regenerative potential upon administration to
damaged hearts.
Although unlikely, a further scenario that should be
considered is the possible presence of an additional “factor” that
would be switched on after P2 to freeze/lock the system in a
fashion in which agrin would not bind α-DG with the same
affinity as before.
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Agrin Exact Timing of Expression in the
Human Heart
The regeneration potential of human cardiac muscular tissue
is considered generally low, although a certain degree of
cardiomyocyte renewal has been observed throughout life, with
a peak reached at 10 years of age followed by a steady decrease
throughout adulthood (Bergmann et al., 2015). The final number
of CMs is reached already around 1 month after birth, but the
exact timing (i.e., days or weeks) and molecular mechanisms
by which the fully proliferative capacity of CMs would be
substantially lost and replaced by a very low efficiency in cell
division is unknown. No specific data have been collected so
far on the transcription/expression levels of agrin or of other
elements of the DGC within the first postnatal weeks, due to
limitations imposed by obvious ethical concerns on the collection
and use of human samples. Therefore, it is not known (i) how
crucial is the role of agrin at different stages of human cardiac
development and/or cardiomyocyte proliferation, (ii) whether
exogenous agrin can exert on human hearts the same effect
observed in mice. In this respect, some encouraging preliminary
results have been obtained also in piglets, a model of MI more
closely related to human cardiac physiology [see the preprint by
Baehr et al. (2019)].
In order to fully grasp the possible therapeutic potential of
agrin in heart regeneration, the levels of agrin in the human
heart should be fully characterized as a function of time, from
the embryonic to the childhood and through to the adult stage.
This is undoubtedly a very challenging task, due to the limitations
cited above that could, however, be at least partially overcome
by analyzing (upon ethical approval and patient consent) peri-
operative samples. Is agrin only expressed until early after birth,
and then not expressed at all? In the light of what has been found
in mice, it would be particularly important to collect data on
the expression of agrin along all human developmental stages,
which is a challenging task, mainly due to the intrinsic difficulties
in collecting representative heart samples. Furthermore, is there
a differential expression of agrin isoforms specific for each
developmental stage? It seems likely that the A0B0 agrin isoform
(the so-called muscle isoform, Gesemann et al., 1996) would be
the most populated during development and neonatal growth,
given that it has the largest affinity for α-DG, but this needs to be
demonstrated yet. Ultimately, for a better therapeutic tailoring,
it could be important to narrow down the expression profiles of
other agrin splice isoforms in the human heart.
“Switching on” an Agrin-Driven Specific
Regenerative Program?
Agrin knockout in mice results in death at birth, but no gross
histological abnormalities have been recorded in cardiac tissues
(Gautam et al., 1996; Burgess et al., 2000). Similar findings have
been described for the only human case reported of an agrin-
null variant leading to perinatal death, (Geremek et al., 2020).
Such evidence strongly indicates that agrin is not essential for CM
proliferation during embryogenesis. This means that the DGC
could well be involved in the sequestration of phosphorylated
YAP at the cytosolic side of sarcolemma but, although agrin can
induce DGC disassembly when administered to postnatal heart,
factors other than agrin (or complementary to it) could induce
the DGC disassembly believed to be responsible for YAP release
during development. What is certain is that administration
of exogenous agrin promotes the activation of this specific
CMs proliferation program in mouse and possibly in larger
mammals, as proposed by Baehr et al. in a very recent preprint
manuscript (Baehr et al., 2019) reporting the regenerative effect
of intracoronary injection of agrin into porcine models of
myocardial infarction.
To the best of our knowledge, there is a lack of evidence
to show that in larger mammals the regeneration mechanism
induced by agrin is an established and conserved genetic program
rather than a “una tantum” effect induced upon administration
of exogenous protein. Again, a thorough investigation to prove
whether a similar agrin-induced mechanism is in place also
in human cardiac tissues, whether during development or/and
exogenously induced, is granted.
Translational Potential of Agrin for Heart
Regeneration: Controlled Delivery of Agrin
to the Damaged Tissues
From a translational point of view, a strategy based on an
agrin-controlled proliferative program that can be triggered from
outside CMs (i.e., within the ECM) should follow one of the
basic principles of drug discovery and carefully consider the
balance likely to exist between the beneficial and deleterious
effects of an exogenous reactivation. In principle, any drug
effective in raising the transcriptional levels of agrin could be
appealing, but an estimate of the specific timing and dosage,
as well of the most effective methods of administration, would
be essential. If agrin is proven to be a competitor of laminin
for binding to α-DG, important results could for example be
obtained by reducing (temporarily) the expression of laminin.
Another possibility would be to promote expression of a tailored
agrin encompassing the α-DG binding site within the damaged
tissues using retroviruses, that are commonly employed for
delivering into cells nucleic acid sequences of interest to be
integrated into the host cells genome. Indeed, a “mini-agrin”
construct that binds to basement membranes as well as to α-
DG has been already devised for use in skeletal muscle (Moll
et al., 2001). Such construct is effective in attenuating the
muscle pathology observed in a mouse model for congenital
muscular dystrophy, through a mechanism that includes agrin-
mediated stabilization of α-DG and the available laminin a5
chain. Retroviral strategies for a prolonged delivery of a series
of therapeutic “mini-agrin” peptides (capable of binding both
laminin and dystroglycan) have been recently proposed for the
treatment of chronic pathologies such as congenital muscular
dystrophies in available mouse model systems (Qiao et al., 2018;
Yurchenco and McKee, 2019). In the case of agrin, “mini-
agrin”, or truncated agrin delivery to diseased cardiac tissue,
complementary strategies should be in place to make the re-
activation highly controlled, as a prolonged delivery of agrin
could induce undesired hyperproliferative effects.
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Both in mouse (Bassat et al., 2017) and porcine (Baehr
et al., 2019) models of myocardial infarction (MI), recombinant
agrin injected locally in the damaged heart seems to have
an overall cardioprotective effect, with anti-inflammatory and
angiogenic components to add to CM protection and (mild)
proliferation induction. As the authors suggest, agrin could then
enhance heart healing via a series of pleiotropic effects, but the
hypothesis that agrin may act through a promiscuous rather than
a specificmechanism bears important implications/repercussions
when trying to envisage regenerative strategies. As an example,
administration of agrin has been shown to stimulate the
production of blood vessels in both murine and porcine MI
(myocardial infarction) models (Baehr et al., 2019), which
draws an analogy with the recently discovered role of agrin
in recruiting endothelial cells within tumors and its ability
to overall promote tumor angiogenesis (Njah et al., 2019).
Specifically, agrin has been found to act in endothelial cells
(ECs) by an ECM stiffness based mechanism similar to that
described in tumor cells, although the mechanotransduction axis
would not involve the activation of YAP/TAZ but rather the
stabilization of VEGFR2 (Vascular Endothelial Growth Factor
Receptor 2), a master regulator of ECs migration, proliferation
and angiogenesis.Whether agrin acts following a similar pathway
also in cardiac angiogenesis is unknown, but since the agrin
isoforms produced within growing tumors by cancer cells
and ECs have a similar angiogenic effect (Njah et al., 2019),
it could be speculated that this specific agrin axis could be
the same acting in cardiac ECs. Paradoxically, even when
administered locally, agrin could thus have beneficial effects on
certain heart cells/tissues, but at the same time be dangerous
for the surrounding ones not directly involved in the damage
and healing process, where it could induce hyperproliferation.
Considering the role of agrin in tumorogenesis and angiogenesis
and the evidences collected on MI models, caution should be
exercised when trying to envisage cardiac regenerative strategies
involving this proteoglycan. In this respect, another crucial point
to also consider in order to further assess the potential benefit
of using therapeutic agrin would be to verify whether this
protein is stimulating the hyperproliferation of human cardiac
fibroblasts, or the activity of other factors involved in fibrotic
tissue formation.
Protein Therapy, Dosage, and Cost
The idea that an in-situ agrin-injection could potentially
prevent or reduce the formation of scar tissue in the injured
heart and stimulate the regrowth of healthy cardiac tissue is
undoubtedly powerful. From an exquisitely biotechnological
point of view, a full biochemical and structural characterization
of the interaction of agrin with its partners primarily on CMs
would be fundamental for the optimization of a series of
parameters typically considered in drug discovery, such as (i)
the solubility and stability of the employed recombinant protein,
(ii) its capacity to trigger the regenerative program with high
specificity, and thus (iii) the most effective dosage (with the
least adverse effects), (iv) the final cost of treatments involving
a recombinant system for the production of full-length agrin,
or of the agrin C-terminal peptides that harbor the α-DG
binding site. To note, as an alternative to local injection more
physiological methods of administration could be employed.
A promising example is offered by cardiac patches made of
natural materials with specific biodegradable and biocompatible
properties emulating closely the myocardial microenvironment
(Albertario et al., 2019; McMahan et al., 2020), to be implanted
upon corrective cardiac surgery. Such patches could be used as a
matrix for storage and controlled release of agrin with different
modalities. As an example, collagen scaffolds have been used
to deliver vascular endothelial growth factor (VEGF) either by
modifying the protein to include a collagen-binding domain
or by seeding the scaffold with cells that have been genetically
engineered to express VEGF, thereby extending the delivery time
and promoting vascular growth in infarcted myocardial tissue
[reviewed by Ye et al. (2013)]. The last frontier would be that of
employing the very latest technologies that created an acellular
cardiac patch composed of synthetic microparticles containing
secreted cardiac regenerative factors embedded in a scaffold
formed by decellularized myocardial ECM (Huang et al., 2020),
to allow release of agrin in the absence of the complications
associated with cellular components. However, it remains to be
determined whether any of the above patches would allow for
the necessary time-restricted controlled delivery of recombinant
agrin to the damaged heart, and local injection might still be
the preferential and more efficient mean of administration, as
recently shown in pig models of MI (Baehr et al., 2019).
CONCLUSIONS
Agrin might represent a new player in the race to find
innovative treatments for the cure of damaged hearts. Although
the preliminary results obtained show great promise, it is
still too early to foresee whether exogenous agrin-induced
heart regeneration could become a realistic therapeutic avenue
for injured human cardiac muscle. A thorough investigation
at the molecular level into the proposed mechanism and a
characterization of the role played by all factors involved will
be pivotal to fully uncover the translational potential of this
regenerative pathway.
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